中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2013年
35期
8-10
,共3页
脑出血%全身炎症反应综合征%白蛋白类%呋塞米
腦齣血%全身炎癥反應綜閤徵%白蛋白類%呋塞米
뇌출혈%전신염증반응종합정%백단백류%부새미
Cerebral hemorrhage%Systemic inflammatory response syndrome%Albumins%Furosemide
目的 探讨白蛋白联合呋塞米在治疗高龄脑出血患者中的疗效与安全性,为临床高龄脑出血患者的治疗提供依据.方法 将200例高龄脑出血患者采用机械抽样法分为对照组和观察组.对照组110例,给予生命体征监测、脏器功能支持、降低颅内压等常规治疗;观察组90例,在对照组治疗基础上,应用白蛋白10g,2次/d,在加用白蛋白后静脉推注呋塞米20 mg,连续应用10d.对两组患者入院时及治疗7、14d后的动脉血乳酸、静脉血清C反应蛋白(CRP)水平及治疗第14天的病死率进行比较.结果 两组患者入院时一般资料比较差异无统计学意义(P>0.05).对照组治疗7、14d后动脉血乳酸水平分别为(2.56±0.63)、(1.98±0.65) mmol/L,均高于观察组的(1.91±0.70)、(1.28±0.68) mmol/L,差异有统计学意义(P<0.05).对照组治疗7、14 d后静脉血清CRP水平分别为(120.02±40.65)、(48.75±30.11)mg/L,均高于观察组的(60.52±30.83)、(13.45±6.02)mg/L,差异有统计学意义(P< 0.05).对照组治疗第14天的病死率为22.73%(25/110),高于观察组的13.33%(12/90),差异有统计学意义(P<0.05).结论 白蛋白联合呋塞米可减轻高龄脑出血患者的炎性反应,降低病死率,疗效与安全性显著,有望成为高龄脑出血患者的常规治疗方案.
目的 探討白蛋白聯閤呋塞米在治療高齡腦齣血患者中的療效與安全性,為臨床高齡腦齣血患者的治療提供依據.方法 將200例高齡腦齣血患者採用機械抽樣法分為對照組和觀察組.對照組110例,給予生命體徵鑑測、髒器功能支持、降低顱內壓等常規治療;觀察組90例,在對照組治療基礎上,應用白蛋白10g,2次/d,在加用白蛋白後靜脈推註呋塞米20 mg,連續應用10d.對兩組患者入院時及治療7、14d後的動脈血乳痠、靜脈血清C反應蛋白(CRP)水平及治療第14天的病死率進行比較.結果 兩組患者入院時一般資料比較差異無統計學意義(P>0.05).對照組治療7、14d後動脈血乳痠水平分彆為(2.56±0.63)、(1.98±0.65) mmol/L,均高于觀察組的(1.91±0.70)、(1.28±0.68) mmol/L,差異有統計學意義(P<0.05).對照組治療7、14 d後靜脈血清CRP水平分彆為(120.02±40.65)、(48.75±30.11)mg/L,均高于觀察組的(60.52±30.83)、(13.45±6.02)mg/L,差異有統計學意義(P< 0.05).對照組治療第14天的病死率為22.73%(25/110),高于觀察組的13.33%(12/90),差異有統計學意義(P<0.05).結論 白蛋白聯閤呋塞米可減輕高齡腦齣血患者的炎性反應,降低病死率,療效與安全性顯著,有望成為高齡腦齣血患者的常規治療方案.
목적 탐토백단백연합부새미재치료고령뇌출혈환자중적료효여안전성,위림상고령뇌출혈환자적치료제공의거.방법 장200례고령뇌출혈환자채용궤계추양법분위대조조화관찰조.대조조110례,급여생명체정감측、장기공능지지、강저로내압등상규치료;관찰조90례,재대조조치료기출상,응용백단백10g,2차/d,재가용백단백후정맥추주부새미20 mg,련속응용10d.대량조환자입원시급치료7、14d후적동맥혈유산、정맥혈청C반응단백(CRP)수평급치료제14천적병사솔진행비교.결과 량조환자입원시일반자료비교차이무통계학의의(P>0.05).대조조치료7、14d후동맥혈유산수평분별위(2.56±0.63)、(1.98±0.65) mmol/L,균고우관찰조적(1.91±0.70)、(1.28±0.68) mmol/L,차이유통계학의의(P<0.05).대조조치료7、14 d후정맥혈청CRP수평분별위(120.02±40.65)、(48.75±30.11)mg/L,균고우관찰조적(60.52±30.83)、(13.45±6.02)mg/L,차이유통계학의의(P< 0.05).대조조치료제14천적병사솔위22.73%(25/110),고우관찰조적13.33%(12/90),차이유통계학의의(P<0.05).결론 백단백연합부새미가감경고령뇌출혈환자적염성반응,강저병사솔,료효여안전성현저,유망성위고령뇌출혈환자적상규치료방안.
Objective To investigate the therapeutic effect and safety of albumin combination furosemide in treatment of eld cerebral hemorrhage patients,and provide evidence for clinical treatment of eld cerebral hemorrhage patients.Methods Two hundred eld cerebral hemorrhage patients were divided into control group (110 cases) and observation group (90 cases) by systematic sampling method.The two groups were given the monitor of vital signs,support of organ function,reduce of intracranial pressure and other conventional treatment,on the basis of which albumin (10 g,2 times/day) and furosemide (20 mg,intravenous injection) were given to observation group for 10 days.The levels of arterial blood lactate and vein serum C reactive protein (CRP) of 2 groups were compared at admission,treatment for 7 and 14 days.Moreover,the mortality rate of 2 groups at 14th day of treatment was also compared.Results There were no statistical differences in the condition of patients between the 2 groups at admission (P > 0.05).The levels of arterial blood lactate of control group at treatment for 7 and 14 days were significantly higher than those of observation group [(2.56 ± 0.63) and (1.98 ± 0.65) mmol/L vs.(1.91 ± 0.70) and (1.28 ± 0.68) mmol/L],there were statistical differences between the 2 groups (P<0.05).The levels of vein serum CRP of control group at treatment for 7 and 14 days were significantly higher than those of observation group [(120.02 ± 40.65) and (48.75 ± 30.11) mg/L vs.(60.52 ± 30.83) and (13.45 ± 6.02) mg/L],there were statistical differences between the 2 groups (P < 0.05).The mortality rate at 14th day of treatment of control group was significantly higher than that of observation group [22.73% (25/110) vs.13.33% (12/90)],there was statistical differences between the 2 groups (P < 0.05).Conclusion Albumin combination furosemide in treatment of eld cerebral hemorrhage patients can relieve the inflammatory reaction and decrease the mortality rate,it is expected to become the routine treatment in eld cerebral hemorrhage patients.